Pharma Mar (UK) Performance
| 0RC6 Stock | 72.55 2.34 3.12% |
On a scale of 0 to 100, Pharma Mar holds a performance score of 19. The company holds a Beta of 0.54, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Pharma Mar's returns are expected to increase less than the market. However, during the bear market, the loss of holding Pharma Mar is expected to be smaller as well. Please check Pharma Mar's semi deviation, coefficient of variation, and the relationship between the mean deviation and downside deviation , to make a quick decision on whether Pharma Mar's historical price patterns will revert.
Risk-Adjusted Performance
19 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Pharma Mar SAU are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady basic indicators, Pharma Mar unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Forward Dividend Yield 0.0185 | Payout Ratio 0.1847 | Last Split Factor 0.083333:1 | Last Split Date 2020-07-22 |
| Begin Period Cash Flow | 149.8 M |
Pharma |
Pharma Mar Relative Risk vs. Return Landscape
If you would invest 4,121 in Pharma Mar SAU on August 24, 2024 and sell it today you would earn a total of 3,134 from holding Pharma Mar SAU or generate 76.05% return on investment over 90 days. Pharma Mar SAU is generating 0.9531% of daily returns and assumes 3.771% volatility on return distribution over the 90 days horizon. Simply put, 33% of stocks are less volatile than Pharma, and 81% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Pharma Mar Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pharma Mar's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pharma Mar SAU, and traders can use it to determine the average amount a Pharma Mar's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2527
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 0RC6 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.77 actual daily | 33 67% of assets are more volatile |
Expected Return
| 0.95 actual daily | 18 82% of assets have higher returns |
Risk-Adjusted Return
| 0.25 actual daily | 19 81% of assets perform better |
Based on monthly moving average Pharma Mar is performing at about 19% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pharma Mar by adding it to a well-diversified portfolio.
Pharma Mar Fundamentals Growth
Pharma Stock prices reflect investors' perceptions of the future prospects and financial health of Pharma Mar, and Pharma Mar fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pharma Stock performance.
| Return On Equity | 0.0032 | |||
| Return On Asset | -0.0065 | |||
| Profit Margin | 0 % | |||
| Operating Margin | 0.12 % | |||
| Current Valuation | 1.19 B | |||
| Shares Outstanding | 221.28 M | |||
| Price To Sales | 98.12 X | |||
| Revenue | 158.15 M | |||
| Gross Profit | 182.7 M | |||
| EBITDA | 4.55 M | |||
| Net Income | 1.14 M | |||
| Total Debt | 43.67 M | |||
| Book Value Per Share | 10.39 X | |||
| Cash Flow From Operations | (13.45 M) | |||
| Earnings Per Share | 5.03 X | |||
| Total Asset | 341.22 M | |||
| Retained Earnings | 142.22 M | |||
About Pharma Mar Performance
Assessing Pharma Mar's fundamental ratios provides investors with valuable insights into Pharma Mar's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Pharma Mar is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Pharma Mar is entity of United Kingdom. It is traded as Stock on LSE exchange.Things to note about Pharma Mar SAU performance evaluation
Checking the ongoing alerts about Pharma Mar for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pharma Mar SAU help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pharma Mar SAU appears to be risky and price may revert if volatility continues | |
| Pharma Mar generates negative cash flow from operations | |
| About 21.0% of the company shares are owned by insiders or employees |
- Analyzing Pharma Mar's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pharma Mar's stock is overvalued or undervalued compared to its peers.
- Examining Pharma Mar's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pharma Mar's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pharma Mar's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pharma Mar's stock. These opinions can provide insight into Pharma Mar's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Pharma Stock Analysis
When running Pharma Mar's price analysis, check to measure Pharma Mar's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharma Mar is operating at the current time. Most of Pharma Mar's value examination focuses on studying past and present price action to predict the probability of Pharma Mar's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharma Mar's price. Additionally, you may evaluate how the addition of Pharma Mar to your portfolios can decrease your overall portfolio volatility.